Open Access Open Access  Restricted Access Subscription Access

Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?


Affiliations
1 Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
 

Objective: The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw," observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case: On August, 2014, a 63- year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from2010 to 2013 presented referring pain in the right mandible. Results: This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions: The authors suggest that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.
User
Notifications
Font Size

Abstract Views: 91

PDF Views: 0




  • Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Abstract Views: 91  |  PDF Views: 0

Authors

Andrea Cassoni
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Umberto Romeo
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Valentina Terenzi
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Marco Della Monaca
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Oriana Rajabtork Zadeh
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Ingrid Raponi
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Maria Teresa Fadda
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Antonella Polimeni
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy
Valentino Valentini
Odontostomatological Science and Maxillo facial Surgery Department, "Sapienza" University of Rome, 00161 Rome, Italy

Abstract


Objective: The acronym MRONJ has been created in order to identify "Medication-Related Osteonecrosis of the Jaw," observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron's disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis. Clinical Case: On August, 2014, a 63- year-old female with a history of idiopathic arthritis treated with medical treatment with Adalimumab from2010 to 2013 presented referring pain in the right mandible. Results: This patient presented with nonexposed osteonecrosis of the jaw after placement, on September, 2010, of four titanium fixtures in the mandible. Conclusions: The authors suggest that the biologic therapy with an anti-TNF-α antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity of the bone.